Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Azmi Nabulsi Sells 9,353 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Azmi Nabulsi sold 9,353 shares of the firm’s stock in a transaction on Monday, April 5th. The stock was sold at an average price of $36.11, for a total value of $337,736.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Azmi Nabulsi also recently made the following trade(s):

  • On Thursday, April 1st, Azmi Nabulsi sold 5,147 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $37.57, for a total value of $193,372.79.
  • On Monday, March 1st, Azmi Nabulsi sold 5,373 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $45.85, for a total value of $246,352.05.
  • On Tuesday, February 2nd, Azmi Nabulsi sold 14,500 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $39.89, for a total value of $578,405.00.

Phathom Pharmaceuticals stock opened at $38.73 on Thursday. Phathom Pharmaceuticals, Inc. has a twelve month low of $27.47 and a twelve month high of $64.54. The stock’s fifty day simple moving average is $43.29 and its 200-day simple moving average is $40.62. The company has a current ratio of 8.21, a quick ratio of 8.21 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $1.21 billion, a P/E ratio of -2.77 and a beta of 1.32.

Phathom Pharmaceuticals (NASDAQ:PHAT) last posted its earnings results on Monday, March 29th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.57). Sell-side analysts predict that Phathom Pharmaceuticals, Inc. will post -3.1 earnings per share for the current year.

A number of equities analysts have weighed in on the company. Needham & Company LLC lifted their price objective on Phathom Pharmaceuticals from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, December 15th. Guggenheim assumed coverage on Phathom Pharmaceuticals in a research note on Tuesday, February 2nd. They issued a “buy” rating and a $60.00 price target for the company. BMO Capital Markets began coverage on Phathom Pharmaceuticals in a research note on Wednesday, February 17th. They issued an “outperform” rating and a $63.00 price target for the company. Jonestrading began coverage on Phathom Pharmaceuticals in a report on Thursday, January 28th. They set a “buy” rating on the stock. Finally, Zacks Investment Research cut Phathom Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, April 3rd. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Phathom Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $50.20.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Citigroup Inc. increased its stake in shares of Phathom Pharmaceuticals by 194.6% during the 4th quarter. Citigroup Inc. now owns 3,294 shares of the company’s stock worth $110,000 after purchasing an additional 2,176 shares in the last quarter. Trexquant Investment LP acquired a new position in shares of Phathom Pharmaceuticals in the 4th quarter valued at $208,000. Virtus ETF Advisers LLC lifted its holdings in shares of Phathom Pharmaceuticals by 6.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 6,635 shares of the company’s stock valued at $220,000 after acquiring an additional 393 shares in the last quarter. Credit Suisse AG acquired a new position in shares of Phathom Pharmaceuticals during the 4th quarter valued at $264,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Phathom Pharmaceuticals by 30.9% during the 4th quarter. Wells Fargo & Company MN now owns 11,289 shares of the company’s stock valued at $375,000 after acquiring an additional 2,662 shares in the last quarter. 73.80% of the stock is owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Featured Story: Compound Interest

Insider Buying and Selling by Quarter for Phathom Pharmaceuticals (NASDAQ:PHAT)

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.